| |
著者: Caitlin W Hicks, Daniel A Sweeney, Xizhong Cui, Yan Li, Peter Q Eichacker
雑誌名: Intensive Care Med. 2012 Jul;38(7):1092-104. doi: 10.1007/s00134-012-2541-0. Epub 2012 Apr 24.
Abstract/Text
PURPOSE: Bacillus anthracis infection (anthrax) can be highly lethal. Two recent outbreaks related to contaminated mail in the USA and heroin in the UK and Europe and its potential as a bioterrorist weapon have greatly increased concerns over anthrax in the developed world.
METHODS: This review summarizes the microbiology, pathogenesis, diagnosis, and management of anthrax.
RESULTS AND CONCLUSIONS: Anthrax, a gram-positive bacterium, has typically been associated with three forms of infection: cutaneous, gastrointestinal, and inhalational. However, the anthrax outbreak among injection drug users has emphasized the importance of what is now considered a fourth disease form (i.e., injectional anthrax) that is characterized by severe soft tissue infection. While cutaneous anthrax is most common, its early stages are distinct and prompt appropriate treatment commonly produces a good outcome. However, early symptoms with the other three disease forms can be nonspecific and mistaken for less lethal conditions. As a result, patients with gastrointestinal, inhalational, or injectional anthrax may have advanced infection at presentation that can be highly lethal. Once anthrax is suspected, the diagnosis can usually be made with gram stain and culture from blood or tissue followed by confirmatory testing (e.g., PCR). While antibiotics are the mainstay of anthrax treatment, use of adjunctive therapies such as anthrax toxin antagonists are a consideration. Prompt surgical therapy appears to be important for successful management of injectional anthrax.
PMID 22527064 Intensive Care Med. 2012 Jul;38(7):1092-104. doi: 10.1007/s00134-012-2541-0. Epub 2012 Apr 24.
|
